Oxybutynin transmucosal - Endo

Drug Profile

Oxybutynin transmucosal - Endo

Alternative Names: AA-4010

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Auxilium Pharmaceuticals
  • Developer Endo International
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Overactive bladder in USA (Transmucosal, Film)
  • 29 Jan 2015 Auxilium Pharmaceuticals has been acquired by Endo International
  • 06 May 2009 Transmucosal oxybutynin is available for licensing (http://www.auxilium.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top